8 completed. 8 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 8 |
| Phase 3 | 3 | Completed 3 |
| Phase 1 | 2 | Completed 2 |
Follow Prostatic Neoplasms, Castration-Resistant: new trials by email Literature Review of Prostatic Neoplasms, Castration-Resistant trials Research Report on Prostatic Neoplasms, Castration-Resistant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer lorigerlimab, docetaxel, Prednisone - Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms | Phase 2 | Completed | MacroGenics | 154 | 2023-09-28 | 2026-05-22 |
| Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer Ipilimumab, Nivolumab - Prostatic Neoplasms, Castration-Resistant | Phase 2 | Completed | Radboud University Medical Center | 69 | 2021-01-19 | 2026-01-06 |
| Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer Etrumadenant, Zimberelimab, Quemliclustat - Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms | Phase 1 / Phase 2 | Completed | Arcus Biosciences, Inc. | 173 | 2020-07-07 | 2025-07-22 |
| Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer Ga-68 PSMA-HBED-CC PET - Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant | Phase 2 / Phase 3 | Completed | Michael Graham PhD, MD | 6 | 2019-03-01 | 2025-04-17 |
| Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects Pembrolizumab, Chemotherapy - Castration Resistant Prostatic Cancer, Metastatic Prostate Cancer | Phase 2 | Completed | University of California, San Francisco | 26 | 2018-02-20 | 2024-11-20 |
| 68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer Ga-68 PSMA-HBED-CC PET - Prostate Cancer, Prostatic Neoplasm | Phase 2 / Phase 3 | Completed | Michael Graham PhD, MD | 30 | 2018-02-16 | 2024-07-12 |
| 68Ga PSMA in Preprostatectomy Patients Ga-68 PSMA-HBED-CC PET - Prostate Cancer, Prostatic Neoplasm | Phase 2 / Phase 3 | Completed | Michael Graham PhD, MD | 22 | 2018-02-16 | 2024-02-15 |
| Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer Autologous dendritic cell - Prostatic Cancer | Phase 1 / Phase 2 | Completed | Samsung Medical Center | 12 | 2006-07-01 | 2010-08-11 |
Genital Diseases (8) · Genital Diseases, Male (8) · Genital Neoplasms, Male (8) · Male Urogenital Diseases (8) · Neoplasms (8) · Neoplasms by Site (8) · Prostatic Diseases (8) · Urogenital Diseases (8) · Urogenital Neoplasms (8) · Prostatic Neoplasms (3)
Docetaxel (2) · CTLA-4 Antigen (1) · Drug Therapy (1) · Ipilimumab (1) · Nivolumab (1) · Prednisone (1) · enzalutamide (1) · pembrolizumab (1) · quemliclustat (1) · sacituzumab govitecan (1) · zimberelimab (1)
Michael Graham PhD, MD (3) · Arcus Biosciences, Inc. (1) · MacroGenics (1) · Radboud University Medical Center (1) · Samsung Medical Center (1) · University of California, San Francisco (1)
United States (6) · Australia (1) · Belgium (1) · Bulgaria (1) · Canada (1) · France (1) · Georgia (1) · Netherlands (1) · Poland (1) · Puerto Rico (1) · South Korea (1) · Spain (1) · United Kingdom (1)
David Oh, MD (1) · J C W, M.D,Ph.D (1) · Michael Graham, MD, PhD (1) · Michael M Graham, Ph.D., MD (1) · Michael M. Graham, MD, PhD (1) · Niven Mehra, PhD (1) · Pepi Pencheva, M.D. (1)
R01CA223484 (1)